Assessment of the mutational profile of the residual clone and the distribution of lymphocyte subpopulations at 3 years of treatment with ibrutinib This project has an epidemiological part: to establish the percentage of patients, in a real-life situation, still undergoing treatment 3 years after its initiation, as well as a biological part: to determine the evolution of the clone and the prevalence of BTK mutations and PLCg2 in the absence of clinical or biological criteria for scalability.
Observationnal and biological study
Study Type
OBSERVATIONAL
Enrollment
198
FILO French Innovative Leukemia Organization
Tours, France
Project manager
Tours, France
Ibrutinib resistance
In the long term, this study will help to draft new recommendations from FILO-LLC concerning the detection of resistance and the management of patients.
Time frame: under treatment at 3 years of ibrutinib
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.